Regulatory News Service (RNS)

View all

Results, Reports and Presentations

• Indivior Q1 2025 Financial Results

  April 24 2025 Download (153KB)

• Annual Report and Accounts 2024

  March 17 2025 Download (7.25MB)

• Indivior FY and Q4 2024 Financial Results

  February 20 2025 Download (589KB)

• Indivior Announces Q3 2024 Financial Results

  October 24 2024 Download (334KB)

• Q2 2024 Results In Line with Updated Guidance; $100m Share Buyback Announced

  July 25 2024 Download (637KB)

View all

Latest News

• New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

  May 1 2025

• Indivior Announces Q1 2025 Financial Results

  April 24 2025

• Indivior Announces Further Changes to Board of Directors

  March 4 2025

• Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

  February 27 2025

• Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

  February 24 2025

View all